THE ROLE OF BIOLOGICAL RESPONSE MODIFIERS IN THE MANAGEMENT OF PATIENTS WITH COLORECTAL-CANCER

被引：5

作者：

WAGSTAFF, J

机构：

来源：

EUROPEAN JOURNAL OF CANCER | 1995年 / 31A卷 / 7-8期

关键词：

COLORECTAL CARCINOMA; BIOLOGICAL RESPONSE MODIFIERS; IMMUNOTHERAPY;

D O I：

10.1016/0959-8049(95)00211-Z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Biological response modifiers are agents which exert their antitumour effects indirectly via modulation of the host's response to the tumour. Immunotherapeutic approaches which fall into this category can be divided into specific and non-specific. An example of the latter is the combination of 5-fluorouracil (5-FU) with levamisole which improves survival of patients with colorectal carcinoma when utilised in an adjuvant setting. Specific immunotherapy using active specific immunisation is attracting much attention. This is in part due to improvements in survival seen in one randomised clinical trial in an adjuvant setting, and also to exciting advances in the fields of tumour immunity and vaccine development. The development of more effective vaccines promises much for patients with early colorectal carcinomas.

引用

页码：1323 / 1325

页数：3

共 29 条

[1]

Laurie, Moertel, Fleming, Et al., Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil, J Clin Oncol, 7, pp. 1447-1456, (1989)

[2]

Moertel, Fleming, MacDonald, Et al., Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma, N Engl J Med, 322, pp. 352-358, (1990)

[3]

Chaplinski, Laszlo, Moore, Et al., Phase II trial of lymphoblastoid interferon in metastatic colon carcinoma, Cancer Treat Rep, 67, pp. 1009-1012, (1983)

[4]

Neefe, Sigals, Ayoob, Et al., Minimal activity of recombinant clone A interferon in metastatic colon cancer, J Biol Response Mod, 3, pp. 366-370, (1984)

[5]

Sigals, Ahlgren, Neefe, A phase II trial of high dose intravenous interferon α-2 in advanced colorectal cancer, Cancer, 56, pp. 2257-2261, (1984)

[6]

Lundell, Blomgren, Cedermark, Et al., High dose rDNA human alpha 2 interferon therapy in patients with advanced colorectal adenocarcinomas—a phase II study, Radiol Oncol, 1, pp. 325-329, (1984)

[7]

Eggermont, Weimer, Marguet, Et al., Phase II trial of high dose recombinant leukocyte α-2 interferon for metastatic colorectal cancer without previous systemic treatment, Cancer Treat Rep, 69, pp. 185-187, (1985)

[8]

Wadler, Lembersky, Atkins, Kirkwood, Petrelli, Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study, J Clin Oncol, 9, pp. 1806-1810, (1991)

[9]

Pazdur, Fluorouracil and recombinant interferon alfa-2a in advanced gastrointestinal neoplasms, BrJ Haemat, 79, pp. 56-59, (1991)

[10]

Grem, McAtee, Murphy, Et al., A pilot study of interferon alfa-2a in combination with fluorouracil plus leucovorin in metastatic gastrointestinal carcinoma, J Clin Oncol, 9, pp. 1811-1820, (1991)

← 1 2 3 →